Elevance Health, Inc. (ELV) Stock Analysis and Metrics

Elevance Health

NYSE: ELV

$377.60 ▼ -1.71 (-0.45%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap82.25 Bn

P/E16.64

P/S0.45

Div. Yield0.02

ROIC (Qtr)0.02

Total Debt (Qtr)31.04 Bn

Revenue Growth (1y) (Qtr)0.02

Add ratio to table…

About

Elevance Health is a leading health company that integrates medical, pharmacy, and behavioral health services to deliver whole health solutions across the care journey. The company operates as one of the largest health insurers in the United States, offering managed care plans and administrative services to individuals, employer groups, Medicaid, Medicare markets, and federal employees through its Federal Health Products & Services business. Through its Blue Cross and Blue Shield licenses in multiple states and its Carelon subsidiaries, Elevance Health aims to improve health outcomes while managing costs for its members and clients.

Elevance Health generates revenue primarily through risk based premiums from its health plans, administrative fees charged to self funded employers for claims processing and related services, and pharmacy and health service fees from its Carelon businesses. Additional income comes from stop loss insurance, dental and vision products, and fees for administering the Federal Employee Program. The company also receives reimbursements from government programs such as Medicare and Medicaid, which are reflected in its health benefit premiums.

The company operates through the following segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other.

• Health Benefits: This segment offers a full suite of medical plans including individual, employer group, Medicare, Medicaid and Federal Employee Program options, and provides administrative services such as claims processing, provider network access and wellness programs to fee based customers.

• CarelonRx: This segment provides pharmacy benefit management services, including home delivery, specialty pharmacy, claims adjudication, formulary management, rebate administration and ambulatory infusion services to both affiliated health plan members and external customers.

• Carelon Services: This segment integrates physical, behavioral, pharmacy and social care capabilities to deliver whole health solutions, offering care management, virtual care, data analytics and provider enablement services to internal and external clients.

• Corporate & Other: This segment includes smaller operating units that do not meet the quantitative thresholds for separate segment reporting, along with corporate level expenses, technology investments and other enterprise wide initiatives not allocated to the other reportable segments.

Elevance Health ranks among the top three health insurers in the United States by membership, competing with UnitedHealth Group, CVS Health and Cigna for national accounts and government sponsored programs. Its competitive advantages stem from the Blue Cross and Blue Shield brand, extensive provider networks, scale based purchasing power and integrated capabilities across insurance, pharmacy and care services that enable it to offer cost effective, coordinated care.

Elevance Health serves individuals purchasing coverage on and off public exchanges, employer groups ranging from small businesses to large multinational corporations, Medicaid and Medicare beneficiaries, federal employees through the Federal Employee Program, and entities that purchase specialty products such as stop loss, dental and vision plans.

Investment Thesis

▲ Bull case

Elevance Health's strategic investments in Carelon are emerging as a significant growth engine with external validation and scalable potential, as evidenced by 50% year-over-year growth in Carelon services and expansion of relationships with external payers including Blues plans for post-acute, behavioral health, specialty care, and palliative solutions. This external traction validates Carelon's operating model beyond internal membership, creating a diversified revenue stream less susceptible to health benefit segment volatility. The integration of acquired assets like CareBridge and the scaling of HealthOS—now supporting over 88,000 providers and 1,200 organizations—enhances care coordination and reduces administrative friction, directly supporting the company's whole health strategy and positioning it to capture value from risk-based contracts that drive nearly $100 in PMPM savings across medical and pharmacy. These initiatives are not merely cost-saving but represent a structural shift toward outcome-based care that aligns with industry trends and payer demands for efficiency, suggesting the market may be underestimating the long-term margin expansion and earnings stability potential from Carelon's scalability.
The company's proactive approach to Medicaid rate alignment and state partnerships demonstrates disciplined execution in a challenging environment, with April adjustments coming in as expected and early discussions underway for the July cohort covering one-third of Medicaid membership. Despite elevated acuity and cost trends, Elevance Health is actively partnering with states to rethink care delivery through its long-term care model that integrates home-based services, behavioral health, and care coordination—delivering better outcomes at lower cost and avoiding ER visits and institutional stays. The recent acquisition of Centers Plan for Health Living in New York further expands this whole health approach, signaling a commitment to sustainable, value-based Medicaid management that could lead to margin recovery as rate updates materialize in the second half of the year. This contrasts with the market's potential overemphasis on near-term Medicaid pressure, overlooking the company's ability to influence rate adequacy through demonstrated cost savings and quality improvements, which could unlock upside to guidance if state negotiations yield favorable outcomes ahead of expectations.
Elevance Health's digital equity initiatives, particularly Get Connected for Health and CareBridge, represent an underappreciated catalyst for improving engagement, reducing avoidable utilization, and enhancing star ratings—especially among dual-eligible and Medicaid populations. By providing smartphones with unlimited data and preloaded health tools, alongside cellular-enabled tablets with 24/7 virtual care access in multiple languages, the company is addressing social determinants of health that directly impact medical costs and member retention. Early results show increased adoption of digital health tools and improved engagement, which translates to better care coordination, fewer gaps in care, and lower total cost of care—particularly relevant as the company scales risk-based models in Medicaid and duals platforms. These programs are not peripheral CSR efforts but strategic levers that improve risk scores, enhance preventive care adherence, and reduce high-cost interventions, suggesting the market may be undervaluing the long-term financial impact of improved health outcomes and operational efficiency derived from closing the digital divide in underserved communities.
The company's disciplined capital allocation and strong balance sheet—evidenced by a 41% debt-to-capital ratio and $5.6 billion in remaining share repurchase authorization—provide significant flexibility to capitalize on opportunities, including the $1.1 billion in Q1 2026 share repurchases at a weighted average price of $304.68. This reflects management's confidence in intrinsic value and signals to the market that excess capital will be returned to shareholders, supporting EPS growth even amid moderate revenue expansion. Combined with operating cash flow of $4.3 billion in Q1 2026 (up $3.3 billion year-over-year) and an outlook for approximately $8 billion annually, Elevance Health has robust internal funding for both strategic investments and shareholder returns. The market may be overlooking how this financial flexibility, coupled with improving claims experience and visibility into medical cost trends, enables sustained EPS accretion through both organic growth and opportunistic capital deployment, particularly as the company executes its repositioning strategy to return to at least 12% adjusted profit growth in 2027.

Elevance Health's strategic investments in Carelon are emerging as a significant growth engine with external validation and scalable potential, as evidenced by 50% year-over-year growth in Carelon services and expansion of relationships with external payers including Blues plans for post-acute, behavioral health, specialty care, and palliative solutions. This external traction validates Carelon's operating model beyond internal membership, creating a diversified revenue stream less susceptible to health benefit segment volatility. The integration of acquired assets like CareBridge and the scaling of HealthOS—now supporting over 88,000 providers and 1,200 organizations—enhances care coordination and reduces administrative friction, directly supporting the company's whole health strategy and positioning it to capture value from risk-based contracts that drive nearly $100 in PMPM savings across medical and pharmacy. These initiatives are not merely cost-saving but represent a structural shift toward outcome-based care that aligns with industry trends and payer demands for efficiency, suggesting the market may be underestimating the long-term margin expansion and earnings stability potential from Carelon's scalability.
The company's proactive approach to Medicaid rate alignment and state partnerships demonstrates disciplined execution in a challenging environment, with April adjustments coming in as expected and early discussions underway for the July cohort covering one-third of Medicaid membership. Despite elevated acuity and cost trends, Elevance Health is actively partnering with states to rethink care delivery through its long-term care model that integrates home-based services, behavioral health, and care coordination—delivering better outcomes at lower cost and avoiding ER visits and institutional stays. The recent acquisition of Centers Plan for Health Living in New York further expands this whole health approach, signaling a commitment to sustainable, value-based Medicaid management that could lead to margin recovery as rate updates materialize in the second half of the year. This contrasts with the market's potential overemphasis on near-term Medicaid pressure, overlooking the company's ability to influence rate adequacy through demonstrated cost savings and quality improvements, which could unlock upside to guidance if state negotiations yield favorable outcomes ahead of expectations.
Elevance Health's digital equity initiatives, particularly Get Connected for Health and CareBridge, represent an underappreciated catalyst for improving engagement, reducing avoidable utilization, and enhancing star ratings—especially among dual-eligible and Medicaid populations. By providing smartphones with unlimited data and preloaded health tools, alongside cellular-enabled tablets with 24/7 virtual care access in multiple languages, the company is addressing social determinants of health that directly impact medical costs and member retention. Early results show increased adoption of digital health tools and improved engagement, which translates to better care coordination, fewer gaps in care, and lower total cost of care—particularly relevant as the company scales risk-based models in Medicaid and duals platforms. These programs are not peripheral CSR efforts but strategic levers that improve risk scores, enhance preventive care adherence, and reduce high-cost interventions, suggesting the market may be undervaluing the long-term financial impact of improved health outcomes and operational efficiency derived from closing the digital divide in underserved communities.
The company's disciplined capital allocation and strong balance sheet—evidenced by a 41% debt-to-capital ratio and $5.6 billion in remaining share repurchase authorization—provide significant flexibility to capitalize on opportunities, including the $1.1 billion in Q1 2026 share repurchases at a weighted average price of $304.68. This reflects management's confidence in intrinsic value and signals to the market that excess capital will be returned to shareholders, supporting EPS growth even amid moderate revenue expansion. Combined with operating cash flow of $4.3 billion in Q1 2026 (up $3.3 billion year-over-year) and an outlook for approximately $8 billion annually, Elevance Health has robust internal funding for both strategic investments and shareholder returns. The market may be overlooking how this financial flexibility, coupled with improving claims experience and visibility into medical cost trends, enables sustained EPS accretion through both organic growth and opportunistic capital deployment, particularly as the company executes its repositioning strategy to return to at least 12% adjusted profit growth in 2027.

▼ Bear case

Elevance Health's Medicare Advantage business faces structural headwinds from the V28 risk model transition and ongoing CMS scrutiny, evidenced by the $935 million accrual for potential exposure related to historical risk adjustment data—a charge that directly impacted Q1 2026 operating gain and contributed to the 34.2% year-over-year decline in total operating gain. While management characterizes this as a current best estimate tied to past practices, the persistence of such adjustments suggests ongoing regulatory risk in Medicare Advantage billing and coding practices that could lead to further financial impacts beyond the current accrual. The company's acknowledgment that it is exiting underperforming MA markets and anticipating declines in Medicare Advantage, Medicaid, and Employer Group risk membership indicates a strategic retreat from growth in its traditionally higher-margin government businesses, raising concerns about the sustainability of its MA franchise value and the potential for margin compression as it repositions for long-term stability rather than expansion.
Medicaid remains a persistent drag on profitability, with the benefit expense ratio increasing 40 basis points year-over-year to 86.8% in Q1 2026 due to expected elevated medical cost trends, and operating gain in the Health Benefits segment declining 2.7% despite 2.6% revenue growth—primarily offset by anticipated higher medical costs in Medicaid. Although rate alignment discussions are underway, the July cohort updates covering one-third of membership are still uncertain, and the company's characterization of Medicaid margin recovery as a "tail of two hogs" implies a prolonged, uneven path to improvement. The reliance on state-level negotiations introduces execution risk, as favorable rate updates are not guaranteed and may lag behind rising acuity and utilization patterns, particularly among complex populations served through duals and home-based services, potentially prolonging pressure on margins and limiting the company's ability to leverage its whole health strategy for near-term earnings growth.
Carelon's external growth, while notable, is being funded by continued investment in risk-based capabilities that have yet to translate into proportional operating gain improvement, as Carelon Services operating gain declined 4.3% year-over-year despite 12.7% revenue growth. This divergence suggests that scaling external relationships—particularly with external payers for post-acute, behavioral health, and specialty care—is currently dilutive to margins due to upfront costs, infrastructure investments, and the inherent risk in value-based contracts where savings realization lags behind delivery. The company's emphasis on Carelon as a strategic growth engine may be premature if external partnerships fail to achieve scalable risk-adjusted profitability quickly enough, especially given the competitive landscape in care coordination and home-based services where larger players and specialized vendors could erode Elevance Health's differentiation, leaving Carelon as a revenue driver without commensurate earnings contribution.
The company's elevated benefit expense ratio of 86.8% and operating expense ratio of 12.8%—up 190 basis points year-over-year—reflect a cost structure under pressure from both medical trends and investments in transformation, with only partial offset from disciplined expense management that improved the adjusted operating expense ratio by just 20 basis points. While net investment income provided a tailwind in Q1 2026 (up 29.7%), this is not a sustainable earnings driver and masks underlying operational weakness in the core insurance businesses. The outlook for at least $26.75 in adjusted EPS for 2026 assumes successful execution of the repositioning strategy and margin recovery in Medicaid and MA, yet the first quarter showed declining operating margins across all major segments—Health Benefits (5.1% vs 5.4%), CarelonRx (5.5% vs 6.0%), and Carelon Services (6.4% vs 7.5%)—suggesting that the market may be overestimating the pace of operational improvement and underestimating the persistent drag from medical cost trend, regulatory risks, and the investments required to sustain long-term competitiveness in a rapidly evolving healthcare landscape.

Elevance Health's Medicare Advantage business faces structural headwinds from the V28 risk model transition and ongoing CMS scrutiny, evidenced by the $935 million accrual for potential exposure related to historical risk adjustment data—a charge that directly impacted Q1 2026 operating gain and contributed to the 34.2% year-over-year decline in total operating gain. While management characterizes this as a current best estimate tied to past practices, the persistence of such adjustments suggests ongoing regulatory risk in Medicare Advantage billing and coding practices that could lead to further financial impacts beyond the current accrual. The company's acknowledgment that it is exiting underperforming MA markets and anticipating declines in Medicare Advantage, Medicaid, and Employer Group risk membership indicates a strategic retreat from growth in its traditionally higher-margin government businesses, raising concerns about the sustainability of its MA franchise value and the potential for margin compression as it repositions for long-term stability rather than expansion.
Medicaid remains a persistent drag on profitability, with the benefit expense ratio increasing 40 basis points year-over-year to 86.8% in Q1 2026 due to expected elevated medical cost trends, and operating gain in the Health Benefits segment declining 2.7% despite 2.6% revenue growth—primarily offset by anticipated higher medical costs in Medicaid. Although rate alignment discussions are underway, the July cohort updates covering one-third of membership are still uncertain, and the company's characterization of Medicaid margin recovery as a "tail of two hogs" implies a prolonged, uneven path to improvement. The reliance on state-level negotiations introduces execution risk, as favorable rate updates are not guaranteed and may lag behind rising acuity and utilization patterns, particularly among complex populations served through duals and home-based services, potentially prolonging pressure on margins and limiting the company's ability to leverage its whole health strategy for near-term earnings growth.
Carelon's external growth, while notable, is being funded by continued investment in risk-based capabilities that have yet to translate into proportional operating gain improvement, as Carelon Services operating gain declined 4.3% year-over-year despite 12.7% revenue growth. This divergence suggests that scaling external relationships—particularly with external payers for post-acute, behavioral health, and specialty care—is currently dilutive to margins due to upfront costs, infrastructure investments, and the inherent risk in value-based contracts where savings realization lags behind delivery. The company's emphasis on Carelon as a strategic growth engine may be premature if external partnerships fail to achieve scalable risk-adjusted profitability quickly enough, especially given the competitive landscape in care coordination and home-based services where larger players and specialized vendors could erode Elevance Health's differentiation, leaving Carelon as a revenue driver without commensurate earnings contribution.
The company's elevated benefit expense ratio of 86.8% and operating expense ratio of 12.8%—up 190 basis points year-over-year—reflect a cost structure under pressure from both medical trends and investments in transformation, with only partial offset from disciplined expense management that improved the adjusted operating expense ratio by just 20 basis points. While net investment income provided a tailwind in Q1 2026 (up 29.7%), this is not a sustainable earnings driver and masks underlying operational weakness in the core insurance businesses. The outlook for at least $26.75 in adjusted EPS for 2026 assumes successful execution of the repositioning strategy and margin recovery in Medicaid and MA, yet the first quarter showed declining operating margins across all major segments—Health Benefits (5.1% vs 5.4%), CarelonRx (5.5% vs 6.0%), and Carelon Services (6.4% vs 7.5%)—suggesting that the market may be overestimating the pace of operational improvement and underestimating the persistent drag from medical cost trend, regulatory risks, and the investments required to sustain long-term competitiveness in a rapidly evolving healthcare landscape.

Customer Breakdown of Revenue (2025)

Peer Comparison

Companies in the Healthcare Plans

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	UNH	Unitedhealth Group Inc	384.70 Bn	30.02	0.90	77.92 Bn
2	CVS	CVS HEALTH Corp	136.05 Bn	46.86	1.84	63.11 Bn
3	ELV	Elevance Health, Inc.	82.25 Bn	16.64	0.45	31.04 Bn
4	CI	Cigna Group	75.16 Bn	11.50	0.75	30.90 Bn
5	HUM	Humana Inc	47.47 Bn	38.91	0.46	13.99 Bn
6	CNC	Centene Corp	31.35 Bn	-4.86	0.17	16.37 Bn
7	MOH	Molina Healthcare, Inc.	10.44 Bn	54.34	0.24	3.77 Bn
8	OSCR	Oscar Health, Inc.	8.62 Bn	-218.95	1.15	0.43 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Customer Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Customer Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password